Biotechnology, or the genetic modification of living materials, has ignited heated debates over trade policy. Innovations in the manipulation of microbes, plants, and animals raises serious ethical questions related to the commoditization and exchange of living organisms. In the arena of trade policy, these ethical questions pose a unique economic dilemma: to what extent should trade policy reflect moral and ethical judgments about the fruits of biotechnology?
Debate on Genetically Modified Foods
The principal cause of the debate surrounding products of biotechnology is the uncertainty of the long-term health and environmental effects of genetically modified living materials. Though many scientists believe GM foods to be safe, a small but influential group of researchers maintain that uncertainty about their effects on human health justifies extreme precaution, including the possible use of trade restrictions. Some supporters of GM foods agree that rigorous testing and research should continue but that in the meantime the benefits of heartier or enriched crops are too great to ignore and are essential in eliminating world hunger and malnutrition. Advocates of sustainable development are also wary of the long-term effects that GM crops could exert on the environment.
Agricultural concerns center on issues of 'genetic pollution' or the genetic flow from GM crops to unmodified plants in the wild. Transfer of genes from GM to wild plants could create health problems in humans, anti-biotic resistance in plants and associated insects, long-term damage to ecosystems, loss of biodiversity, and lack of consumer choice.
Defenders of biotechnology often argue that genetic manipulation holds the key to eliminating hunger and suffering across the world. One commonly cited example is 'Golden rice' which scientists have engineered to produce extra Vitamin A. The rice has been hailed as a godsend for malnourished people in the developing world because Vitamin A helps prevent blindness. Critics take two different stances on these wonder-foods. Some refer to recent studies and statements by doctors that Golden rice is not a sufficient source of vitamin A. Specifically, people with diarrheal diseases are incapable of absorbing vitamin A from the rice, thus people in developing countries who commonly suffer from diarrheal disease and vitamin A deficiency remain afflicted by both. Other critics reply that 'Franken foods' are the wrong answer to the problems of hunger and malnutrition, which they claim are the outcomes of distributional problems. Instead of posing a viable long-term solution, GM foods distract from and exacerbate the real issues involved.
Patenting Life
Biotechnology issues related to intellectual property rights are concerned with the moral and ethical implication of patenting living organisms. These concerns are linked to fears that biotechnology will transfer resources from the public sphere to private ownership via the enforcement of intellectual property rights. Firms that have invested in the development of genetically modified varieties want to protect their proprietary knowledge, but many farmer groups have protested that enforcing intellectual property rights will disrupt their access to seed. Farmers accustomed to harvesting and replanting their seeds are not willing to pay for GM seeds year after year. These debates draw attention to the controversial TRIPs Article 27.3(b), which exempts certain life forms from patentability but requires countries to establish some form of protection for plant varieties.
GM Food and Hunger
Producers of GM crops argue that biotechnology could be the world's cure for hunger. They cite the technology's ability to produce high yields, resist natural disasters such as drought and certain viruses, and be enriched with vital nutrients that starving people are likely to lack.
However, aid agencies and anti-GM countries argue that in regards to eliminating world hunger, alternatives to GM crop production have not been sufficiently researched. In fact, they note that many countries where hunger is a major problem do produce adequate amounts of food to feed their population. Hunger, they argue, is not only a function of agricultural yield; it is also a function of mismanaged government and a series of other factors, which technology cannot resolve.
At present there is no international law dealing with aid shipments of GM crops to needy countries. However, debates over a country's right to refuse GM food aid during a famine are bringing this issue to the forefront of biotechnology concerns.
Multiple Forums for Debate
There are a number of forums attempting to guide the international debate on biodiversity. At the WTO level, the March 8, 2004 TRIPS Council meeting saw the nations of Brazil, Bolivia, Cuba, Ecuador, India, Pakistan, Peru, Thailand and Venezuela called for greater urgency in resolving possible conflicts between the TRIPS agreement and the Convention on Biological Diversity (CBD). [1] The Convention was established with the three main goals of conservation of biological diversity, sustainable use of its components and the fair and equitable sharing of the benefits from the use of genetic resources. [2] The CBD is concerned with preservation while the TRIPS agreement examines the intersection of business and biodiversity and so there would naturally be conflicts between the different missions of the two arenas. The U.S. and Japan have called for discussions to take place in the World Intellectual Property Organization (WIPO) forum instead which is mandated to increase intellectual property protection. Meanwhile, free trade agreements continue to change the intersection of trade law and biotechnology. For instance the U.S.-Central American Free Trade Agreement encourages plant patentability, a step beyond that of the TRIPS agreement, reflecting the U.S. desire for intellectual property protection to encourage innovation. It also and forbids reversion to weaker patent laws once stronger laws have been enacted. [3]
Current Events
Since 1998, the EU has placed a moratorium on the import of genetically modified living materials, citing insufficient proof that these organisms do not cause long-term negative effects to public health. The ban has frustrated the US, the largest producer of genetically modified crops, and it has long been threatening to file a formal complaint with the WTO over the EU ban, citing the ban as unjustified and discriminatory. In July 2003, however, the EU lifted the five-year ban on the condition that all products containing at least 0.9% genetically altered ingredients be explicitly labeled as such. Despite this move, which would finally allow US farmers of genetically altered crops access to European markets, the US, Canada, Argentina, Brazil and numerous other countries filed a formal complaint with the WTO in May 2003. They argued that the EU's moratorium on the approval of new GM foods violated WTO rules, and cost their farmers hundreds of millions of dollars in lost revenues each year. [4] These countries have also expressed dissatisfaction with the EU's new stipulation that all GM foods be labeled, but the EU has called the complaint unnecessary in light of their new policy toward GM foods. In March 2004 a WTO panel was appointed to rule on the US-Argentina-Canada complaint against the EU de facto moratorium on the approval of new GMOs. [5] (See also the GTN SPS/TBT page.)
The issue of biotechnology's ability to battle hunger has also manifested itself in the complicated cases of 6 African nations, who have banned GMO food aid. [6] Zambia rejected GM food aid while it was hard hit by a famine in 2003 for health and environmental reasons. [7] Zambia voiced concern that GM seed might contaminate their local crop, thus jeopardizing their ability to continue shipping organically grown crops to the EU. The fear that millions in Zambia might starve proved false and the nation ended up producing a 120,000 ton surplus. [8] US food aid which most likely contain GM crops had to be rerouted by the UN World Food Program which distributes the aid. The US has said that it is impossible in practice to keep separate GM foods from non-GM foods. [9]
Conclusion
Biotechnology and its products have created some amazing possibility as well as raised fears among many of their potential negative consequences. There is also the moral dimension of playing with living beings. Nevertheless, the technology and its products are here to stay. GM foods highlight both the potential and the problems with this technology. Foods like "golden rice" may one day ensure that malnutrition is never a concern. However, the fears and uncertainty of its impact on health and the environment have raised important ethical issues as in the case of Zambia turning down GM food aid while in the midst of a famine.
Last updated April 2004.
[1] BRIDGES Monthly Review. Year 8, Number 3, March 2004. [2] http://www.biodiv.org/doc/publications/guide.asp [3] http://www.biodiv.org/doc/publications/guide.asp [4] http://www.usda.gov/news/releases/2003/05/0157.htm [5] http://www.ictsd.org/weekly/04-03-10/wtoinbrief.htm#2 [6] http://www.guardian.co.uk/gmdebate/Story/0,2763,1182378,00.html [7] Southern Africa; Controversy rages over 'GM' food aid. AllAfrica Africa News. February 12, 2003. [8] http://www.guardian.co.uk/gmdebate/Story/0,2763,1182378,00.html [9] http://www.news24.com/News24/Africa/News/0,6119,2-11-1447_1509711,00.html
Read more from the original source:
Biotechnology - Harvard University
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022